1 results match your criteria: "USA hNorth Manchester General Hospital[Affiliation]"
Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
AIDS
April 2014
aCommunity Research Initiative of New England, Boston, Massachusetts bUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA cHospital La Paz, Madrid, Spain dHIV Program Hennepin County Medical Center, Minneapolis, Minnesota, USA eUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany fHoldsworth House Medical Practice, Darlinghurst, New South Wales, Australia gDepartment of Infectious Disease, Kaiser Los Angeles Medical Center, Los Angeles, California, USA hNorth Manchester General Hospital, Manchester, UK iGilead Sciences, Foster City, California, USA.
Objectives: To compare the safety and efficacy of the two single-tablet regimens (STRs), rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) and efavirenz/emtricitabine/tenofovir DF (EFV/FTC/TDF), in HIV-1-infected, treatment-naive adults.
Design: This is a phase 3b, randomized, open-label, multicenter, international, 96-week study.
Methods: Participants were randomized 1:1 to receive either RPV/FTC/TDF or EFV/FTC/TDF.